Yang J, et al. - In this retrospective study. of 50 eyes of 46 people with subtype 1 and 2 polypoidal choroidal vasculopathy (PCV) followed up for at least 60 months classified into three regimens, ie, anti-vascular endothelial growth factor (VEGF) monotherapy, photodynamic therapy (PDT) combining with anti-VEGF therapy initially, and PDT combining with deferred anti-VEGF therapy, experts assessed 5-year outcomes of anti-VEGF monotherapy and combination therapy of anti-VEGF agents and PDT for PCV in a real-world Chinese population. In comparison with subtype 1 PCV, in the real world, subtype 2 PCV had a more favorable visual outcome. All the regimens displayed unfavorable visual outcomes for subtype 1 PCV. Moreover, in the long-term management of subtype 2 PCV, anti-VEGF monotherapy and initial combination therapy should be preferred over deferred combination therapy.